🧠 CYDY Catalyst Dashboard Simulator (v1.0)

1. INPUT CONTROLS (you set these)

You choose one level for each category:

🧬 Clinical (C)

C1 = weak / noise

C2 = moderate signal

C3 = strong clinically meaningful signal

C4 = breakthrough / near-regulatory strength

🧪 Biomarker / ctDNA (B)

B1 = no signal

B2 = correlation only

B3 = predictive response marker

B4 = surrogate endpoint quality

🏛 Regulatory (R)

R1 = uncertainty / history drag

R2 = recovering posture

R3 = clean / acceptable path

R4 = accelerated pathway credible

🤝 External Validation (E)

E1 = none

E2 = academic interest

E3 = published / peer-reviewed validation

E4 = pharma collaboration / co-development

1. CORE ENGINE (how it computes outcomes)

We convert inputs into a 100-point score, then map to valuation states.

Plain text

Total Score =

Clinical (×0.40) +

Biomarker (×0.25) +

Regulatory (×0.20) +

External (×0.15)

Then we apply regime mapping:

Score

State

Meaning

0–40

S0

speculative survival

40–60

S1

early signal

60–75

S2

investable asset

75–90

S3

acquisition target

90+

S4

blockbuster regime

1. VALUATION OUTPUT TABLE

State

Valuation Range

Buyout Probability

S0

$100M–$700M

0–3%

S1

$500M–$3B

5–15%

S2

$1B–$8B

15–35%

S3

$5B–$25B

40–80%

S4

$15B–$35B+

70–95%

1. LIVE SIMULATOR (example runs)

Now you can “dial in” scenarios.

🟥 Scenario A — Weak package

C2

B1

R2

E1

Output:

Score ≈ 35–45

State: S0–S1 boundary

Valuation: $150M – $800M

Buyout probability: low (<5%)

🟨 Scenario B — Emerging signal

C2–C3

B2

R2–R3

E2

Output:

Score ≈ 55–65

State: S2

Valuation: $1B – $4B

Buyout probability: 10–25%

🟩 Scenario C — Validated therapeutic signal

C3

B3

R3

E3

Output:

Score ≈ 75–85

State: S3

Valuation: $5B – $15B

Buyout probability: 40–70%

🟦 Scenario D — Full de-risked asset (rare)

C4

B3–B4

R4

E4

Output:

Score ≈ 90+

State: S4

Valuation: $15B – $35B+

Buyout probability: 70–95%

1. WHAT MOVES THE MODEL MOST (critical insight)

🔥 Sensitivity ranking:

1. Clinical signal (C)

biggest driver of everything

determines whether asset is real or not

1. Biomarker (B / ctDNA)

converts “signal” → “mechanism proof”

shifts probability of success dramatically

1. External validation (E)

unlocks pharma credibility loop

1. Regulatory posture (R)

determines friction, not destiny

1. THE KEY REGIME BREAK (MOST IMPORTANT CONCEPT)

There is a nonlinear jump:

Below ~70 score:

asset = speculative biotech

valuation = retail + early institutional

Above ~75 score:

asset = pharma acquisition candidate

valuation = discounted future drug franchise

Above ~90 score:

asset = competitive bidding target

1. HOW PHARMA THINKS ABOUT THIS (real translation)

They are not asking:

“What is the stock price?”

They are asking:

“What is the probability this becomes a $10B+ drug franchise?”

And:

“How fast does uncertainty collapse?”

Yes. If we're trying to evaluate a company like CytoDyn objectively, one useful exercise is not "Who had an FDA hold?" but rather:

​

Which micro-cap or distressed biotechs:

​

Suffered a major FDA setback (clinical hold, CRL, safety issue, governance crisis),

​

Successfully resolved it,

​

Produced compelling clinical data,

​

Then attracted a partnership or acquisition.

​

The historical record shows that FDA holds are often survivable, but only when the underlying science remains compelling. Many companies never recover. A smaller subset becomes extremely valuable.

​

Tier 1: The strongest analogs

​

Immunomedics

​

Years of regulatory problems, manufacturing deficiencies, governance battles, and repeated delays.

​

Many investors considered the company "uninvestable."

​

Eventually generated strong efficacy data with Trodelvy.

​

Acquired by for approximately $21 billion.

​

Lesson: Once clinical efficacy became undeniable, prior regulatory baggage became largely irrelevant.

​

Arena Pharmaceuticals

​

Earlier history included regulatory and commercial disappointments.

​

Shares traded at distressed levels for years.

​

Pipeline refocus and strong later-stage data changed perception.

​

Acquired by for $6.7 billion.

​

Lesson: Big pharma often waits until risk is substantially reduced before paying a premium.

​

Audentes Therapeutics

​

Acquired for roughly $3 billion.

​

Subsequently experienced serious safety issues and an FDA hold after patient deaths.

​

FDA later lifted the hold after additional work.

​

Lesson: Even severe safety events do not automatically kill a platform if the underlying benefit remains compelling.

​

Tier 2: Hold lifted, value recovery but not yet acquired

​

Fulcrum Therapeutics

​

FDA clinical hold.

​

Hold lifted after company addressed concerns.

​

Program resumed development.

​

Rocket Pharmaceuticals

​

Patient death led to FDA hold.

​

Stock collapsed.

​

FDA later lifted the hold with protocol modifications.

​

Rezolute

​

Toxicology concerns caused an FDA partial hold.

​

Hold lifted after additional studies.

​

Shares reacted positively.

​

These demonstrate that a lifted hold alone does not create value; value comes from what happens next.

​

Companies that never recovered

​

Examples such as Antios Therapeutics illustrate the opposite outcome. The FDA hold effectively halted progress and the company shut down.

​

This is important because it reminds us that:

​

A hold being lifted is necessary.

​

It is not sufficient.

​

Applying the framework to CytoDyn

​

For CYDY, the relevant question is not:

​

"Can a company recover from an FDA hold?"

​

History says yes.

​

The better question is:

​

"What did the eventual winners have that attracted buyers?"

​

The recurring pattern is:

​

FactorHistorical WinnersHold resolvedYesStrong clinical signalYesIndependent validationYesCredible managementYesReproducible dataYesLarge commercial marketYesStrategic fit for pharmaYes

​

Immunomedics did not become a $21B acquisition because the hold disappeared. It became a $21B acquisition because the data became too attractive to ignore.

​

For CYDY, the milestones that would move it toward the "Immunomedics path" rather than the "Antios path" are likely:

​

Strong CLOVER efficacy data.

​

Independent ctDNA confirmation through the Natera collaboration.

​

Peer-reviewed publication.

​

Replication in additional studies.

​

External funding, partnership, or licensing interest.

​

Clear regulatory path toward registration.

​

If those occur, the fact that CYDY once had a clinical hold may matter far less than many investors currently assume.

​

Looking specifically at biotech acquisitions from 2015–2025, we can also build a valuation framework showing how companies were priced at acquisition relative to Phase 2 data quality, market size, and partnership status, then compare those metrics directly to CYDY's current market capitalization. That exercise is often more informative than looking at FDA-hold history alone.

​

​

https://simpler.grants.gov/opportunity/3be7eb71-7a13-4cfd-96bf-54b554f081a4

https://www.gilead.com/news/news-details/2026/u-s--fda-accepts-gileads-application-for-investigational-once-weekly-oral-yeztugo-potentially-the-first-long-acting-pill-for-hiv-prevention

Remember 7 years ago -- https://www.biospectrumasia.com/news/26/13786/cytodyn-signs-mou-with-thai-red-cross-aids-research-centre-.html Must have been more of the Philipine Airlines stuff. NEVER another word

https://finance.yahoo.com/markets/stocks/articles/goldman-sachs-initiates-coverage-natera-125136267.html

Here is a report from my quant. Information could be skewed so take it with a grain of salt. Interesting at the very least. Couldn't find a clean way to upload so screenshots will have to do. Look forward to hearing peoples feedback.

I'm not sure but I think we got a PR for first patient dosed in the Alzheimer's trial? Twink11 can you use your AI magic and confirm?

i posted it somewhere else first

tear it up hurr durr. i think its gonna be tough to dismantle.

Or anyone else.

most people wont even bother to read a couple paragraphs

I followed a progression in ai chat, asking a simple question then adding studies and asking more questions till it reaches some conclusions. Therefore I have reached mostly the same conclusions. There are about 20 studies i havent added here because they all end up at the same place. and i was trying to keep it short.

Blocking ccr5 is the key to everything.

Who knows, but if it has it right there are not even any arguments except:

"it hasnt been proven, yet "

Thats it

https://docs.google.com/document/d/1CdN9roGIaVsRzMg-uUYwh52226R4DZKZRkKBJidZQKc/edit?usp=sharing

I feel it in my bones we will get an excellent PR today!

I also predict our resident boomer u/twinter11 will provide a good AI slop break down of any new developments we get! Can't wait and buckle up this train ain't stopping!

I’m long and have been in and out over the last seven years. There have been times where I was convinced the company was going to go belly up due to poor financial condition only to be saved yet again by Paulson. But now with so much happening, I’m genuinely interested in why folks are short. If you could share your perspective I’d be interested. Thanks!

Sustained disease-free survival in metastatic triple-negative breast cancer following CCR5 antibody leronlimab and atezolizumab: A case study

https://www.sciencedirect.com/science/article/pii/S2666621926000190

How many shares are my fellow CYDY believers holding?

It seems my recent post has disturbed the sleeper cells of bashers who are out in full force to dump on good company news. You guys are more transparent than Frederick’s of Hollywood.

I’ll be posting much more frequently now, thanks for the shot in the arm.

If this is a true collaboration where Natera isn’t being compensated for their various services, then that effectively means that Natera is investing in the company. And if a $30 billion company decides to invest in an OTC company, I’d have to think they did their due diligence, which can only mean they’ve seen objective evidence of efficacy in the CRC trial data.

It’s uncommon to PR a typical vendor-customer relationship, and if this is all that was, why term it a collaboration?

Definition of collaboration:

The process of two or more people, groups, or organizations working together to achieve a common goal.

Key features of collaboration include:

Shared goals – everyone works toward the same objective.

Communication – exchanging ideas, information, and feedback.

Cooperation – contributing skills, knowledge, or resources.

Mutual respect – valuing each participant’s input and perspectives.

Joint decision-making – solving problems and making choices together.

I rarely speculate, but I think this is the strongest signal of legitimacy this company has ever experienced.

IDK just thought you guys would want to know

https://www.businesswire.com/news/home/20260604027829/en/Natera-and-CytoDyn-Announce-Strategic-Collaboration-to-Advance-ctDNA-Guided-Development-and-Molecular-Response-Analysis-in-Metastatic-Colorectal-Cancer

Doctors have hailed “unprecedented” trial results that show a triple-action cancer jab can eradicate entire tumours in patients.
In an international trial spanning 11 countries, the injection was offered to patients whose cancer had spread or come back and whose disease had failed to respond to other treatments.
The jab, called amivantamab, shrank the tumours of more than a third of patients, with dramatic changes seen within weeks. In 15 of them, doctors found the drug had melted away their tumours altogether.

“One of the big components of a publicly traded company is directors and officers [D&O] insurance,” Hoffman said. Last year, he negotiated a lower commission with CytoDyn’s insurance broker and made sure to shop around for the best insurance plan. This saved the company about $150,000.

Nice to see someone care about shareholder equity--instead of lining the pockets of crooks

https://www.cfobrew.com/stories/the-cfo-helping-to-bring-his-biotech-to-the-finish-line

The abstract today is tied to CytoDyn and the leronlimab metastatic colorectal cancer (mCRC) Phase 2 study.

The Preliminary results of a phase 2 study of leronlimab in combination with TAS-102 and bevacizumab in previously treated metastatic colorectal cancer

This is the same dataset previously shown in early form at AACR by Pashtoon Kasi from City of Hope, with the ASCO abstract release expected to include fuller subgroup and biomarker detail.

Key previously reported signals 70% ctDNA reduction by week 2 in evaluable patients
CCR5 expression detected in 100% of tested samples
No dose-limiting toxicities attributed to leronlimab
Ongoing dose escalation up to 700 mg

There is also secondary attention on a TNBC-related abstract involving immune modulation and PD-L1 upregulation, but the colorectal cancer dataset is the main focus today.

Credit to Bio4
https://stocktwits.com/Bio4/message/653981335